Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer

被引:8
作者
Hyslop, Terry [1 ]
Weinberg, David S. [2 ]
Schulz, Stephanie [1 ]
Barkun, Alan [3 ]
Waldman, Scott A. [1 ]
机构
[1] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA
[2] Fox Chase Canc Ctr, Dept Med, Philadelphia, PA 19111 USA
[3] McGill Univ, Div Gastroenterol, Dept Med AB, Montreal, PQ, Canada
关键词
lymph node collection; colorectal cancer; molecular staging; occult tumor burden; guanylyl cyclase C; GUANYLYL CYCLASE-C; COLON-CANCER; SURVIVAL; MICROMETASTASES; DISPARITIES; RECURRENCE; EXPRESSION; CARCINOMA; DISEASE; MARKER;
D O I
10.1002/jso.23051
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives Recurrence in lymph node-negative (pN0) colorectal cancer suggests the presence of undetected occult metastases. Occult tumor burden in nodes estimated by GUCY2C RT-qPCR predicts risk of disease recurrence. This study explored the impact of the number of nodes analyzed by RT-qPCR (analytic) on the prognostic utility of occult tumor burden. Methods Lymph nodes (range: 2-159) from 282 prospectively enrolled pN0 colorectal cancer patients, followed for a median of 24 months (range: 263), were analyzed by GUCY2C RT-qPCR. Prognostic risk categorization defined using occult tumor burden was the primary outcome measure. Association of prognostic variables and risk category were defined by multivariable polytomous and semi-parametric polytomous logistic regression. Results Occult tumor burden stratified this pN0 cohort into categories of low (60%; recurrence rate (RR)?=?2.3% [95% CI 0.14.5%]), intermediate (31%; RR?=?33.3% [23.744.1%]), and high (9%; RR?=?68.0% [46.585.1%], P?<?0.001) risk of recurrence. Beyond race and T stage, the number of analytic nodes was an independent marker of risk category (P?<?0.001). When >12 nodes were analyzed, occult tumor burden almost completely resolved prognostic risk classification of pN0 patients. Conclusions The prognostic utility of occult tumor burden assessed by GUCY2C RT-qPCR is dependent on the number of analytic lymph nodes. J. Surg. Oncol. 2012; 106:2430. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:24 / 30
页数:7
相关论文
共 40 条
[1]   Analytical Performance of a qRT-PCR Assay to Detect Guanylyl Cyclase C in FFPE Lymph Nodes of Patients With Colon Cancer [J].
Beaulieu, Martin ;
Desaulniers, Marie ;
Bertrand, Nicolas ;
Deschesnes, Rena G. ;
Beaudry, Guillaume ;
Garon, Genevieve ;
Haince, Jean-Francois ;
Houde, Michel ;
Holzer, Timothy J. .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2010, 19 (01) :20-27
[2]   Polytomous logistic regression analysis could be applied more often in diagnostic research [J].
Biesheuvel, C. J. ;
Vergouwe, Y. ;
Steyerberg, E. W. ;
Grobbee, D. E. ;
Moons, K. G. M. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2008, 61 (02) :125-134
[3]   Prognostic impact of micrometastases in colon cancer - Interim results of a prospective multicenter trial [J].
Bilchik, Anton J. ;
Hoon, Dave S. B. ;
Saha, Sukamal ;
Turner, Roderick R. ;
Wiese, David ;
DiNome, Maggie ;
Koyanagi, Kazuo ;
McCarter, Martin ;
Shen, Perry ;
Iddings, Douglas ;
Chen, Steven L. ;
Gonzalez, Maria ;
Elashoff, David ;
Morton, Donald L. .
ANNALS OF SURGERY, 2007, 246 (04) :568-577
[4]   Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract [J].
Birbe, R ;
Palazzo, JP ;
Walters, R ;
Weinberg, D ;
Schutz, S ;
Waldman, SA .
HUMAN PATHOLOGY, 2005, 36 (02) :170-179
[6]   Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer [J].
Cagir, B ;
Gelmann, A ;
Park, J ;
Fava, T ;
Tankelevitch, A ;
Bittner, EW ;
Weaver, EJ ;
Palazzo, JP ;
Weinberg, D ;
Fry, RD ;
Waldman, SA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (11) :805-+
[7]   Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues [J].
Carrithers, SL ;
Barber, MT ;
Biswas, S ;
Parkinson, SJ ;
Park, PK ;
Goldstein, SD ;
Waldman, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14827-14832
[8]   Differences in colorectal carcinoma stage and survival by race and ethnicity [J].
Chien, C ;
Morimoto, LM ;
Tom, J ;
Li, CI .
CANCER, 2005, 104 (03) :629-639
[9]   The staging of colorectal cancer: 2004 and beyond [J].
Compton, CC ;
Greene, FL .
CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (06) :295-308
[10]   Colorectal cancer [J].
Cunningham, David ;
Atkin, Wendy ;
Lenz, Heinz-Josef ;
Lynch, Henry T. ;
Minsky, Bruce ;
Nordlinger, Bernard ;
Starling, Naureen .
LANCET, 2010, 375 (9719) :1030-1047